FISPB
BMRN icon

Fideuram - Intesa Sanpaolo Private Banking’s BioMarin Pharmaceuticals BMRN Stock Holding History

Fideuram - Intesa Sanpaolo Private Banking’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229 Sell
4
-26,284
-100% -$1.44M ﹤0.01% 442
2026
Q1 		$1.49M Sell
26,288
-5,703
-18% -$333K 0.05% 252
2025
Q4 		$1.9M Buy
+31,991
New +$1.74M 0.07% 227

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return

Fideuram - Intesa Sanpaolo Private Banking's BMRN Position: Q2 2026 in Review

Fideuram - Intesa Sanpaolo Private Banking reduced its BioMarin Pharmaceuticals (BMRN) stake by 100% in Q2 2026, selling an estimated $1.44M and leaving 4 shares worth $229. The position accounts for ﹤0.01% of the portfolio, ranked #442.

Fideuram - Intesa Sanpaolo Private Banking first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.9M in Q4 2025. 272 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Fideuram - Intesa Sanpaolo Private Banking held 4 shares of BioMarin Pharmaceuticals worth $229 as of Q2 2026.
  • Fideuram - Intesa Sanpaolo Private Banking sold 26,284 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Fideuram - Intesa Sanpaolo Private Banking's portfolio in Q2 2026, its #442 holding.
  • Fideuram - Intesa Sanpaolo Private Banking first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Fideuram - Intesa Sanpaolo Private Banking's BioMarin Pharmaceuticals position peaked at $1.9M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Fideuram - Intesa Sanpaolo Private Banking's 13F filing for Q2 2026, filed 23 Jul 2026.